Insider filing
Traded Nov 20, 2025 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 29, 2025 · Filed Oct 31, 2025
A Regeneron Pharmaceuticals director sold $424K of Regeneron Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$424,242
Shares × reported transaction price
1 day after results of Oct 28, 2025, 75 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $652.91 on Oct 29, 2025, 35% above its 52-week low and 29% below its high, after a 12% rise over the previous 30 trading days
52-week range $483.07 (Jun 5, 2025) to $922.79 (Oct 30, 2024), 39% of the way up, from 250 adjusted closes. 30 trading days earlier: $585.50 on Sep 17, 2025. Describes the past only, not a forecast
RSI 73, 9% above its 200-day average, 13% above its 50-day average, 29% below the 52-week high, 20-day volatility 46% a year, against the S&P 500: +13 points over 1 month, +11 points over 3 months, −15 points over 6 months
From the adjusted closes up to Oct 29, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Libtayo on Oct 29, 2025, the same day as this trade.
New use approved (efficacy supplement). Active ingredient: Cemiplimab-Rwlc. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.9% | −0.3% | +2.2% |
| 30 days | +12.7% | +0.1% | +12.6% |
| 90 days | +17.6% | +1.8% | +15.8% |
| 180 days | +10.4% | +5.1% | +5.4% |
| 365 days | +51.5% | +10.4% | +41.2% |
Past results only. Not a forecast.
Insider filing
Traded Nov 20, 2025 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Nov 20, 2025 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Bonnie L Bassler (Director) sold ~$570K of Regeneron Pharmaceuticals
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.